Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04061512
Title Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London
Indications

Waldenstroem's macroglobulinemia

Therapies

Cyclophosphamide + Dexamethasone + Rituximab

Ibrutinib + Rituximab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.